作者
DH Miller, D Soon, KT Fernando, DG MacManus, GJ Barker, TA Yousry, E Fisher, PW O'Connor, JT Phillips, CH Polman, L Kappos, M Hutchinson, E Havrdova, FD Lublin, G Giovannoni, A Wajgt, R Rudick, F Lynn, MA Panzara, AW Sandrock
发表日期
2007/4/24
期刊
Neurology
卷号
68
期号
17
页码范围
1390-1401
出版商
Lippincott Williams & Wilkins
简介
Background: In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with relapsing multiple sclerosis (MS), natalizumab significantly reduced the relapse rate by 68% and progression of sustained disability by 42% vs placebo. We report the effect of natalizumab on MRI measures from the AFFIRM study.
Methods: The number and volume of gadolinium (Gd)-enhancing, new or enlarging T2-hyperintense, and new T1-hypointense lesions and brain parenchymal fraction were measured from annual scans obtained at baseline, 1 year, and 2 years.
Results: Compared with placebo, natalizumab produced a 92% decrease in Gd-enhancing lesions (means 2.4 vs 0.2; p < 0.001), an 83% decrease in new or enlarging T2-hyperintense lesions (means 11.0 vs 1.9; p < 0.001), and a 76% decrease in new T1-hypointense …
引用总数
2007200820092010201120122013201420152016201720182019202020212022202320248271618332430343629262020241112126
学术搜索中的文章